Lee-Sepsick Kathy 4
4 · FEMASYS INC · Filed Mar 27, 2026
Research Summary
AI-generated summary of this filing
Femasys (FEMY) CEO Lee‑Sepsick Receives 68,244 Series D-1 Warrants
What Happened
Kathy Lee‑Sepsick, CEO of Femasys, was granted 68,244 Series D-1 warrants on March 19, 2026. These are derivative securities (warrants) that give the holder the right to buy common stock at an initial exercise price of $0.58 per share (subject to adjustment). The grant was issued in a private placement as consideration under an Omnibus Amendment and Consent Agreement.
Key Details
- Transaction date: 2026-03-19; Form 4 filed: 2026-03-27 (appears to be filed after the typical 2-business-day Form 4 deadline).
- Security: 68,244 Series D-1 warrants (derivative acquisition, code A).
- Initial exercise price: $0.58 per share (total implied cash needed to exercise all warrants ≈ $39,582), subject to standard adjustments (splits, dividends, recapitalizations).
- Exercise limitations: Holder’s ability to exercise the warrants is subject to Nasdaq Capital Market rules and other warrant terms.
- Issuance reason: Reported as consideration in a private placement tied to an Omnibus Amendment and Consent Agreement dated March 19, 2026.
- Shares owned after transaction: Not specified in the filing.
Context
Warrants are not the same as common stock — they are the right to purchase shares later at a set price. This grant does not immediately increase common‑stock voting power or directly realize cash unless and until the warrants are exercised. The exercise price and Nasdaq limits may restrict timing and economics of any future conversion to common shares.
Insider Transaction Report
- Award
Series D-1 Warrants
[F1][F3][F2]2026-03-19+68,244→ 68,244 totalExercise: $0.58From: 2026-03-19Exp: 2036-03-19→ Common stock, par value $0.001 per share (68,244 underlying)
Footnotes (3)
- [F1]Holder may, at its option, exercise the Series D-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.58 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series D-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.
- [F2]The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.
- [F3]The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026 by and among the Company, the reporting person and the other parties thereto.